Table 1.
Variables | All (n = 80) | NCSE (n = 31) | Non-NCSE (n = 49) | P-value |
---|---|---|---|---|
Age, median (IQR) | 78.5 (66.0,87.0) | 83 (74.0,87.0) | 76 (64.5–86.5) | 0.148 |
Female, n (%) | 44 (55.0%) | 21 (67.7%) | 23 (46.9%) | 0.068 |
Hyper-early treatment, n (%) | 51 (63.8%) | 17 (54.8%) | 34 (69.4%) | 0.187 |
Low GCS score, n (%) | 33 (41.3%) | 18 (58.1%) | 15 (30.6%) | 0.015 |
State of consciousness | 0.008 | |||
Lethargy, n (%) | 32 (40.0%) | 6 (19.4%) | 26 (53.1%) | |
Stupor, n (%) | 24 (30.0%) | 11 (35.5%) | 13 (26.5%) | |
Coma, n (%) | 24 (30.0%) | 14 (45.2%) | 10 (20.4%) | |
Location of foci | 0.724 | |||
Left, n (%) | 22 (27.5%) | 10 (32.3%) | 12 (24.5%) | |
Right, n (%) | 43 (53.8%) | 16 (51.6%) | 27 (55.1%) | |
Bilateral, n (%) | 15 (18.8%) | 5 (16.1%) | 10 (20.4%) | |
Hemorrhagic transformation, n (%) | 21 (26.3%) | 11 (35.5%) | 10 (20.4%) | 0.135 |
Cortical injury, n (%) | 49 (61.3%) | 24 (77.4%) | 25 (51.0%) | 0.018 |
Atrial fibrillation, n (%) | 43 (53.8%) | 18 (58.1%) | 25 (51.0%) | 0.538 |
Diabetes, n (%) | 25 (31.3%) | 10 (32.3%) | 15 (30.6%) | 0.877 |
Hypertension, n (%) | 61 (76.3%) | 24 (77.4%) | 37 (75.5%) | 0.854 |
Smoking, n (%) | 12 (15.0%) | 2 (6.5%) | 10 (20.4%) | 0.167 |
BMI, mean ± SD | 24.2 ± 4.0 | 23.6 ± 4.3 | 24.7 ± 3.8 | 0.204 |
hBA1C, median (IQR) | 5.8 (5.4, 6.3) | 5.7 (5.4,6.2) | 5.8 (5.5,6.5) | 0.181 |
Low-density lipoprotein, mean ± SD | 2.8 ± 1.1 | 2.7 ± 0.9 | 2.8 ± 1.2 | 0.547 |
Homocysteine, median (IQR) | 15.7 (11.8, 20.5) | 17.1 (11.9,23.7) | 14.9 (11.5,19.8) | 0.432 |
Creatinine, median (IQR) | 82.3 (61.2, 103.8) | 83.0 (61.0,107.3) | 80.6 (62.0,94.4) | 0.671 |
Urea, median (IQR) | 6.3 (4.7, 8.4) | 7.1 (4.5,8.4) | 6.1 (4.7,8.3) | 0.898 |
Uric acid, mean ± SD | 369.3 ± 130.6369 | 362.9 ± 134.8 | 373.3 ± 129.2 | 0.949 |
Neuron-specific enolase, median (IQR) | 16.8 (14.0, 23.6) | 17.8 (14.1,35.0) | 16.4 (13.9,21.0) | 0.189 |
NCSE, Non-convulsive status epilepticus; BMI, Body mass index; HbA1c, glycosylated hemoglobin.